Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Non-small cell lung cancer
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
Related Questions
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Does anyone have experience obtaining sunvozertinib in the second-line setting for patients with EGFR exon 20 insertion mutations?
How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?
What are your top takeaways in thoracic cancers from ESMO 2025?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
In NSCLC, would you manage other MET alterations, such as a MET T618T mutation, in the same way as a MET exon 14 skipping mutation?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
How would you respond to a patient with early-stage resectable NSCLC who has a clinical complete response to neoadjuvant chemo-IO, but subsequently declines surgery, not feeling it's necessary anymore?
